Company Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-18 pm EDT 5-day change 1st Jan Change
20.22 USD -3.67% Intraday chart for Pacira BioSciences, Inc. -7.29% -40.07%

Business Summary

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Number of employees: 712

Sales per Business

USD in Million2022Weight2023Weight Delta
Non-opioid Pain Management and Regenerative Health Solutions
100.0 %
667 100.0 % 675 100.0 % +1.22%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
667 100.0 % 675 100.0 % +1.22%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 Jan. 01
Director of Finance/CFO 63 11-10-31
Chief Tech/Sci/R&D Officer 49 21-06-30
Compliance Officer 50 -
Chief Administrative Officer 50 11-11-30
Chief Operating Officer 62 19-05-31
Investor Relations Contact - 15-03-31
Corporate Officer/Principal 52 23-04-18
Corporate Officer/Principal 45 12-03-20

Members of the board

Members of the board TitleAgeSince
Chairman 64 11-06-01
Director/Board Member 64 06-11-30
Director/Board Member 66 11-06-01
Director/Board Member 69 13-06-11
Director/Board Member 45 23-10-09
Director/Board Member 54 23-10-09
Director/Board Member 46 23-10-09
Director/Board Member 63 17-06-14
Director/Board Member 62 23-10-09
Director/Board Member 61 19-09-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 46,546,148 45,808,785 ( 98.42 %) 0 98.42 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.30 %
7,586,818 16.30 % 217 M $
Vanguard Fiduciary Trust Co.
10.99 %
5,113,384 10.99 % 146 M $
Frontier Capital Management Co. LLC
4.113 %
1,914,343 4.113 % 55 M $
1,903,612 4.090 % 54 M $
Renaissance Technologies LLC
4.044 %
1,882,197 4.044 % 54 M $
Pacer Advisors, Inc.
3.379 %
1,572,705 3.379 % 45 M $
Macquarie Investment Management Business Trust
3.354 %
1,561,039 3.354 % 45 M $
DFA Australia Ltd.
3.354 %
1,561,005 3.354 % 45 M $
Stephens Investment Management Group LLC
3.065 %
1,426,745 3.065 % 41 M $
ClearBridge Investments LLC
2.518 %
1,172,150 2.518 % 34 M $

Company contact information

Pacira Biosciences, Inc.

5401 West Kennedy Boulevard Suite 890

33609, Tampa

+813 553 6680

http://www.pacira.com
address Pacira BioSciences, Inc.(PCRX)
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
20.22 USD
Average target price
41.78 USD
Spread / Average Target
+106.62%
Consensus
  1. Stock Market
  2. Equities
  3. PCRX Stock
  4. Company Pacira BioSciences, Inc.